According to Royalty Pharma's latest financial reports the company's total debt is $6.13 B. A companyโs total debt is the sum of all current and non-current debts.
Year | Total debt | Change |
---|---|---|
2023-12-31 | $6.13 B | -13.79% |
2022-12-31 | $7.11 B | 0.29% |
2021-12-31 | $7.09 B | 22% |
2020-12-31 | $5.81 B | -6.76% |
2019-12-31 | $6.23 B | -4.31% |
2018-12-31 | $6.51 B |
Company | Total debt | differencediff. | Country |
---|---|---|---|
Abbott Laboratories ABT | $15.62 B | 154.72% | ๐บ๐ธ USA |
Eli Lilly LLY | $25.22 B | 311.15% | ๐บ๐ธ USA |
ANI Pharmaceuticals ANIP | $0.28 B | -95.34% | ๐บ๐ธ USA |